BRAF and neoplasm: This is further underlined by recent studies showing that targeted inhibition of mutated BRAF may cause tumor regression in metastatic melanomas harboring BRAF V600E mutations [12, 13], as well as findings indicating that treatment of BRAF-mutated melanomas may benefit from inhibition of the downstream effector MEK [14].